Lifecore Biomedical Ownership
| LFCR Stock | 7.49 0.19 2.47% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 34 M | Current Value 37 M | Avarage Shares Outstanding 28.5 M | Quarterly Volatility 2.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Lifecore Stock Ownership Analysis
About 72.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.47. Lifecore Biomedical had not issued any dividends in recent years. To find out more about Lifecore Biomedical contact James Hall at (952) 368-4300 or learn more at https://www.lifecore.com.Besides selling stocks to institutional investors, Lifecore Biomedical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Lifecore Biomedical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Lifecore Biomedical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Lifecore Biomedical Quarterly Liabilities And Stockholders Equity |
|
Only 1.3% of Lifecore Biomedical are currently held by insiders. Unlike Lifecore Biomedical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Lifecore Biomedical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Lifecore Biomedical's insider trades
Lifecore Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lifecore Biomedical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lifecore Biomedical backward and forwards among themselves. Lifecore Biomedical's institutional investor refers to the entity that pools money to purchase Lifecore Biomedical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2025-03-31 | 235.1 K | Quinn Opportunity Partners Llc | 2025-03-31 | 153.4 K | Tocqueville Asset Management L.p. | 2025-03-31 | 151.7 K | Lpl Financial Corp | 2025-03-31 | 145.9 K | Ubs Group Ag | 2025-03-31 | 110.2 K | Millennium Management Llc | 2025-03-31 | 100.8 K | Goldman Sachs Group Inc | 2025-03-31 | 88 K | Gamco Investors, Inc. Et Al | 2025-03-31 | 84.5 K | Bank Of New York Mellon Corp | 2025-03-31 | 83.7 K | Wynnefield Capital Inc | 2025-03-31 | 4.7 M | Legion Partners Asset Management, Llc | 2025-03-31 | 4.4 M |
Lifecore Biomedical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lifecore Biomedical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lifecore Biomedical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lifecore Biomedical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lifecore Biomedical Outstanding Bonds
Lifecore Biomedical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lifecore Biomedical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lifecore bonds can be classified according to their maturity, which is the date when Lifecore Biomedical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Lifecore Biomedical Corporate Filings
8K | 18th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 29th of May 2025 Other Reports | ViewVerify | |
F3 | 16th of April 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Pair Trading with Lifecore Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving together with Lifecore Stock
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.